MedTrace Logo

Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?

NCT04469634 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-03-06

No results posted yet for this study

Summary

The objectives of this study are (1) to determine the ex vivo neutralizing capacity and the longevity of SARS-CoV-2-specific Ab responses and (2) to measure the memory B-cell responses in a cohort of health care workers (HCW) recovering from severe, mild or asymptomatic infection. By focusing on HCW, a population that is at risk for re-infection during a second epidemic wave, the correlation between nAb levels and protection is investigated.

Conditions

Interventions

DIAGNOSTIC_TEST

Assessing antibody responses, neutralizing capacity and memory B-cell function

Assessing antibody responses, neutralizing capacity and memory B-cell function and their contribution to protection against re-infection

Sponsors & Collaborators

  • Jessa Hospital

    collaborator OTHER

  • University Hospital, Antwerp

    collaborator OTHER

  • Universiteit Antwerpen

    collaborator OTHER

  • Sciensano

    collaborator OTHER_GOV

  • Mensura

    collaborator UNKNOWN

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Kevin K. Ariën, PhD · Institute of Tropical Medicine Antwerp

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469634 on ClinicalTrials.gov